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Abstract
Background: Phytoestogens are a group of lipophillic plant compounds that can have estrogenic
effects in animals; both tumorigenic and anti-tumorigenic effects have been reported. Prolactin-
secreting adenomas are the most prevalent form of pituitary tumors in humans and have been
linked to estrogen exposures. We examined the proliferative effects of phytoestrogens on a rat
pituitary tumor cell line, GH3/B6/F10, originally subcloned from GH3 cells based on its ability to
express high levels of the membrane estrogen receptor-α.
Methods: We measured the proliferative effects of these phytoestrogens using crystal violet
staining, the activation of several mitogen-activated protein kinases (MAPKs) and their downstream
targets via a quantitative plate immunoassay, and caspase enzymatic activities.
Results: Four phytoestrogens (coumestrol, daidzein, genistein, and trans-resveratrol) were studied
over wide concentration ranges. Except trans-resveratrol, all phytoestrogens increased GH3/B6/F10
cell proliferation at some concentration relevant to dietary levels. All four phytoestrogens
attenuated the proliferative effects of estradiol when administered simultaneously. All
phytoestrogens elicited MAPK and downstream target activations, but with time course patterns
that often differed from that of estradiol and each other. Using selective antagonists, we
determined that MAPKs play a role in the ability of these phytoestrogens to elicit these responses.
In addition, except for trans-resveratrol, a serum removal-induced extrinsic apoptotic pathway was
blocked by these phytoestrogens.
Conclusion: Phytoestrogens can block physiological estrogen-induced tumor cell growth in vitro
and can also stimulate growth at high dietary concentrations in the absence of endogenous
estrogens; these actions are correlated with slightly different signaling response patterns.
Consumption of these compounds should be considered in strategies to control endocrine tumor
cell growth, such as in the pituitary.
Background
Phytoestrogens are defined functionally as plant-derived
compounds that promote estrogenic actions in mammals,
and are somewhat structurally similar to the potent mam-
malian estrogen, 17β-estradiol (E2) (see Figure 1). The
diverse biological activities of phytoestrogens may be due
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in part to their ability to act as either estrogen agonists or
antagonists, depending on the dose and the specific tissue
in which they are active. These abilities have caused a lot
of attention to be focused on these compounds as poten-
tial safe, effective, and inexpensive estrogen replacement
therapeutics. Estrogens can influence the growth and
functioning of both female and male reproductive tissues,
maintain the skeletal and central nervous systems, and
provide protective effects in the cardiovascular system [1].
However, prolonged estrogen exposures have also been
linked to the development of cancer in tissues such as
breast, colon, and pituitary [2-4]. So it is important to
determine which of these estrogenic attributes are shared
by phytoestrogens.
Phytoestrogens have been shown to bind to two types of
estrogen receptors (ERs, α and β) [5,6] and perhaps also
to act via the alternative ER, GPR30 [7], Although this
class of estrogens can elicit effects via the genomic path-
way, those nuclear actions have in the past been described
as weak for most phytoestrogens. We instead hypothe-
sized that some actions of phytoestrogens relevant to con-
trol of cell numbers could be via plasma membrane forms
of these receptors, which use rapid enzymatic cascades
and ion fluxes to elicit relatively rapid functional
responses. These actions have, however, remained largely
untested. Here we asked these questions in a cell line
selected for its high level of membrane ERα expression,
and its ability to display a variety of rapid estrogenic
responses [8-10]. However, it is probable that both types
of mechanistic pathways (nuclear and membrane) are
involved in a function as complex as cell proliferation.
For these experiments we examined three different types
of phytoestrogens and their effects on pituitary tumor cell
growth. The first group is coumestans, represented in our
studies by coumesterol. Coumesterol was first reported to
be estrogenic in 1957 [11] when it was associated with
disrupting reproduction in livestock. It is found in dietary
sources such as legumes, clover, and sprouts of soybeans
and alfalfa. The reported average serum concentration
resulting from ingesting these foods in humans is approx-
imately 0.01 μM [12]. The second group is isoflavones,
represented by daidzein and genistein in our experiments.
The major source of isoflavonoids in the diet is soy-based
foods. In Asia, the intake of soy can be as high as 30-50 g
a day and plasma concentrations of genistein from 0.1 to
10 μM have been measured [12,13]. Western diets usually
contain about ten-fold lower concentrations [14]. We also
studied  trans-resveratrol, a stilbene, which is found in
high quantities in foods such as red grapes (wine) and
peanuts. There are two isomers of resveratrol, cis and trans,
but only the trans form has been reported to be estrogenic
[15]. Trans-resveratrol has high bioavailability and rela-
tively high physiological levels can be obtained through
drinking red wine. The peak serum concentration of trans-
resveratrol and its metabolites was estimated to be close to
2 μM in humans [16]. All of these phytoestrogens in our
studies have been shown to have estrogenic and anti-
estrogenic effects, depending on the types and develop-
mental status of tissues.
Prolactinomas develop from prolactin-secreting lac-
totropes in the anterior pituitary gland and are the most
frequently occurring neoplasm of the human pituitary.
Hyperprolactinemia can cause reproductive dysfunctions
such as amenorrhea, galactorrhea and infertility in
women, and impotence and reduced reproductive hor-
mones levels in men. It is also associated with some
behavioral disturbances [17,18]. Estrogen exposures are
linked to prolactinomas in both animals and humans.
Women using oral contraceptives due to menstrual irreg-
ularities show a 7-8 fold higher incidence of prolactino-
mas, and male transsexuals undergoing sex change
therapies also have a higher incidence of these tumors [4].
Subcutaneous implants of diethylstilbestrol cause pitui-
tary hyperplasia and neoplasms in Fischer F344 rats
[19,20]. Pituitaries also normally respond to estrogens by
undergoing cell proliferation in response to pregnancy
level estrogens; under these conditions the number of
prolactin-secreting cells and serum prolactin content
increases. Although the exact mechanism by which estro-
gens increase mitogenesis is not completely understood,
this increased proliferation response can sometimes result
The structure of estradiol compared to phytoestrogens Figure 1
The structure of estradiol compared to phytoestro-
gens. Chemical structures of the phytoestrogenic com-
pounds used in this study are presented, compared to the 
physiological estrogen E2.
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in prolactinomas. Increased production and secretion of
prolactin, and induction and activation of cell cycle regu-
latory proteins leading to a more rapid rate of cell division
may eventually lead to uncorrected genetic errors, result-
ing in the activation of oncogenes or inactivation of sup-
pressor genes, genomic instability, and transformation
[21].
Mitogen-activated protein kinases (MAPKs) control many
aspects of mammalian cellular physiology, including cell
growth, differentiation and apoptosis, and they respond
to a variety of mitogens and growth factors. They can also
phosphorylate downstream targets such as Elk-1 and ATF-
2 transcription factors [22,23]. Activating these down-
stream targets of MAPKs can influence chromatin remod-
eling and gene expression affecting cell proliferation
[24,25]. There are three major MAPK types including
extracellular signal-regulated kinases (ERKs), c-JUN N-ter-
minal kinases (JNKs) and p38 kinases. Recently, we found
that estrogens (both physiological and environmental)
can rapidly activate ERKs via membrane ERα (mERα) and
non-genomic pathways in GH3/B6/F10 cells [26]. There-
fore, we became interested in the possibility that phytoes-
trogens may also activate MAPKs, and play a role in how
estrogens elicit or inhibit cell proliferation.
Due to the possible undesirable side effects of estrogenic
stimulation (such as increases in tumor risks), many
women have turned to phytoestrogens as an alternative
for hormone replacement therapy. This is based on the
idea that in Asian cultures where these dietary estrogens
are present in much higher exposure levels than in West-
ern diets, that the diseases attributable to estrogen loss
(hot flashes and bone, brain, and cardiovascular tissue
decline) are significantly less evident, and the diseases of
estrogen overexposure (cancer of reproductive tissues) are
also significantly lower. Therefore, it has been reasoned
that these plant estrogens may be safe and effective
replacements that do not increase cancer risks. There is a
rapidly growing body of literature on the functional con-
sequences of phytoestrogen use, and the biochemical
characteristics of the compounds, their metabolites, and
their cellular response systems, especially for soy prod-
ucts. But, little investigation has thus far addressed the
question of whether phytoestrogens can cause pituitary
tumor cell growth, and if so, via what nongenomic mech-
anisms this might occur.
Methods
We purchased phenol red-free Dulbecco modified Eagle
medium (DMEM, high glucose) from Mediatech (Hern-
don, VA); horse serum from Gibco BRL (Grand Island,
NY); defined supplemented calf sera and fetal bovine sera
from Hyclone (Logan, UT). Paraformaldehyde and glutar-
aldehyde were purchased from Fisher Scientific (Pitts-
burgh, PA). Antibodies used in the measurement of levels
of phosphorylaed MAPKs and their downstream targets
were purchased from Cell Signaling Technology (Danvers,
MA). Kinase phospho-antibodies recognize more than
one member of each family of kinase. The MAPK inhibi-
tors, and the substrates and blockers for caspase assays
were purchased from Biomol (Plymouth Meeting, PA). All
other materials were purchased from Sigma (St. Louis,
MO).
GH3/B6/F10 cells are routinely cultured in DMEM contain-
ing 12.5% horse serum, 2.5% defined supplemented calf
serum, and 1.5% fetal calf serum. They are then switched
to various hormone-free media prior to our experiments,
as described below. Cells were used between passages 10
to 20.
Proliferation assays
Subconfluent cells growing in serum-containing medium
were seeded into 96-well plates coated with poly-D-lysine
(5000 cells/well), allowed to attach overnight, and treated
with E2 or various phytoestrogens in DMEM medium con-
taining 1% 4× charcoal-stripped FBS for 3 days. Cell num-
bers were assessed by the crystal violet assay to compare
the proliferative effects of phytoestrogens at different con-
centrations. On the day of cell number analysis, cells from
which medium had been removed were fixed for 20 min
in 2% paraformaldehyde and 0.1% glutaraldehyde in
PBS. They were then stained for 30 min with a 0.1% solu-
tion of crystal violet, and destained in deionized water.
The dye was released with 10% acetic acid at RT for 30
min, and the A590 signal of the extract was then read in a
model 1420 Wallac microplate reader (Perkin Elmer,
Waltham, MA). We used 8 samples for each treatment
group, and experiments were repeated 3 times using dif-
ferent passages of cells.
MAPKs, Elk-1, and ATF-2 assays
We originally developed this assay to assess activated ERK
1 and 2 levels in fixed GH3/B6/F10 cells [10] and subse-
quently adapted it to equivalent assays for p38s and JNKs,
and now in this study for the phosphorylated transcrip-
tion factors Elk-1 and ATF-2. Briefly, cells were plated at a
density of 10,000 cells/poly-D-lysine-coated well in 96-
well plates. The following day growth media were
replaced with DMEM containing 1% charcoal-stripped
(4×) serum (to deprive cells of steroids) for 48 hr. Cells
were then washed with DMEM once before the E2 or the
phytoestrogens (or 0.0001% ethanol vehicle) were added
for 2.5 to 60 min. We routinely used cholesterol as a neg-
ative control and phorbol 12-myristate 13-acetate as a
positive control. The cells were then fixed with 2% para-
formaldehyde/0.2% picric acid at 4°C for 48 hr. After fix-
ation, the cells were permeabilized with PBS containing
2% BSA and 0.1% Triton X-100 for 1 hr at RT, washed 3×BMC Cancer 2009, 9:334 http://www.biomedcentral.com/1471-2407/9/334
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with PBS, and primary antibody (Ab) against phosphor-
ylated ERKs (p-Thr202/Tyr204; 1:400 in PBS/1% BSA),
phosphorylated JNK (p-Thr183/Tyr185; 1:500 in PBS/1%
BSA), phosphorylated p38 (p-Thr180/Tyr182; 1:500 in
PBS/1% BSA), phosphorylated Elk-1 (p-Ser383; 1:750 in
PBS/1% BSA), or phosphorylated ATF-2 (p-Thr69/71,
1;500 in PBS/1%BSA) was added. After overnight incuba-
tion at 4°C, the cells were washed 3× with PBS, and the
biotin-conjugated secondary Ab (Vector Labs, Burlingame
CA, 1:300) in PBS/1% BSA was added for 1 hr at RT. The
cells were again washed with PBS, incubated with
Vectastain ABC-AP solution (Vector Labs) for 1 hr at RT,
and again washed 3× with PBS, followed by addition of
Vectastain alkaline phosphatase substrate plus levamasole
(an endogenous phosphatase inhibitor). Plates were incu-
bated in the dark for 30 min at 37°C, and the signal for
the phosphatase product para-nitrophenol was read at
A405 in a model 1420 Wallace microplate reader. The
number of cells in each well was determined by the crystal
violet assay (as described above) and used to normalize
phosphorylated enzyme values to cell numbers in individ-
ual wells. The experiments were repeated at least 3 times
using different passages of cells on different days.
Caspase activity assays
Subconfluent cells growing in serum-containing medium
were seeded into 96-well plates coated with poly-D-lysine
(5000 cells/well), allowed to attach overnight, and treated
with E2 or various phytoestrogens in DMEM medium con-
taining 1% 4× charcoal-stripped FBS for 1 day. Cells were
spun down, washed with ice-cold PBS, and 100 μl of lysis
buffer (10 mM Hepes, pH 7.4, 2 mM EDTA 0.1% CHAPs),
to which 5 mM DTT and proteinase inhibitor (from
Sigma) were added. To perform the caspase activity assay,
50 μl of the cell lysates were then mixed with 50 μl of cas-
pase assay buffer (50 mM Hepes, pH 7.4, 100 mM NaCl,
0.1% CHAPs, 1 mM EDTA, 10% glycerol, 10 mM DTT)
containing 50 μM of substrate Ac-IETD-AFC (specific for
caspase-8) or Ac-LEHD-AFC (specific for caspase-9), and
incubated at 37°C in the dark. The enzymes catalyzed
release of a fluorescent product (AFC) which was moni-
tored at times 0 and 1 hr using a spectrofluorometer
(GeminiXS, Molecular Devices) at an excitation wave-
length of 400 nm and an emission wavelength of 505 nm.
The cell number in each sample are measured by the crys-
tal violet assay and showed no significant changes at dif-
ferent time points and treatments. The caspase activity is
expressed as change in fluorescence intensity during an hr
for 2500 cells.
Statistics
Data from cell number measurements, and MAPK and
transcription factor assays were analyzed by one-way anal-
ysis of variance (ANOVA) followed by multiple compari-
sons versus control group (Holm-Sidak method). The
Sigma Stat 3 program (Systat Software, Inc.) was used for
all statistical analysis, and significance was accepted at p <
0.05.
Results
Phytoestrogens change the proliferation of GH3/B6/F10 
cells
We first determined the proliferative effects of different
phytoestrogens in GH3/B6/F10 cells over a 9 day time
course, compared to E2, to choose a day when the differ-
ential effects of the compounds were clearly manifested.
We chose the concentrations for growth analyses based on
the published dietary concentrations of these com-
pounds, and compared the effects to those caused by cho-
lesterol, the structurally similar precursor for all steroid
hormones (which did not induce a growth response com-
pared to the ethanol vehicle control). A horizontal bar on
each graph (Figure 2, B-F) shows an estimate of the dietary
concentration ranges for these compounds that have been
measured in serum. Most compounds demonstrated sta-
tistically maximal proliferative effects by day 3 (Figure 2A)
in these extensively hormone-stripped serum conditions.
Comparable proliferative activities were caused by 10-9 M
E2, 10-8 M coumesterol, 10-7 M daidzein and 10-7 M genis-
tein on day 3. Daidzein caused a less robust response on
subsequent days. Trans-resveratrol and cholesterol at a
concentration of 10-7 M showed no proliferative effects on
any of the days tested. We then examined the potency
with which each compound caused proliferation on day
3, in comparison to E2. E2 significantly increased cell
number at a wide range of concentrations from 10-14 to
10-6 M (Figure 2B). Coumestrol caused proliferation from
10-9 to 10-6 M concentrations (Figure 2C). Weaker effects
were observed for daidzein and genistein, both of which
increased cell number only with high concentrations of
10-7 and 10-6 M (Figure 2D and 2E), which are still how-
ever at levels obtainable by ingestion of these compounds
in a typical Asian human diet. Trans-resveratrol did not
cause cell proliferation at any concentration examined
(Figure 2F).
Phytoestrogens attenuate the proliferative effects of E2
To examine the anti-proliferative effects of phytoestro-
gens, we co-treated the GH3/B6/F10 cells with either of two
concentrations representing low and high endogenous
levels (10-12 M or 10-9 M) of E2, plus different concentra-
tions in log increments of coumesterol, daidzein, genis-
tein, or trans-resveratrol (Figure 3). Coumesterol showed
the most anti-proliferative effects, all concentrations
higher than 10-12 M blocking the effects of 10-12 or 10-9 M
of E2 (Figure 3A). Daidzein at concentrations ≥10-10 M
attenuated proliferative effects of either 10-12 or 10-9 M E2,
but the proliferative effects of 10-9 M E2 were not com-
pletely blocked (Figure 3B). Genistein at 10-11 to 10-6 M
concentrations attenuated the proliferative effects of bothBMC Cancer 2009, 9:334 http://www.biomedcentral.com/1471-2407/9/334
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Proliferative effects of E2 and phytoestrogens on GH3/B6/F10 cells Figure 2
Proliferative effects of E2 and phytoestrogens on GH3/B6/F10 cells. (A) Cells treated with physiological or dietary levels 
of estrogens: 10-9 M E2, 10-8 M coumesterol (Cou), 10-7 M cholesterol (negative control), daidzein (Dai), genistein (Gen), or 
trans-resveratrol (Res) over a 9 day time course. Cell proliferation was measured by the crystal violet assay. (B-F) Dose-
response profiles of the proliferative effects of different concentrations of estrogens after 3 days of treatment. (B) E2, (C) cou-
mesterol, (D) daidzein, (E) genistein, and (F) trans-resveratrol. The solid horizontal line spans the reported concentrations of 
each estrogen in human serum or urine. * = p < 0.05 compared to vehicle-treated cells.
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10-12 or 10-9 M of E2 (Figure 3C). Trans-resveratrol concen-
trations higher than 10-12  M blocked the proliferative
effects of 10-12 M E2 completely, but similar to daidzein,
trans-resveratrol only decreased the cell number by about
15% when combined with 10-9 M E2 (Figure 3D). Interest-
ingly, the anti-proliferative effects of phytoestrogens
require lower concentrations than the proliferative effects.
Compared to the expected dietary levels seen in Asian
diets (see horizontal bars), these proliferation-inhibiting
effects might reasonably be expected to be seen with con-
centrations obtainable by eating foods containing them.
Phosphorylation of MAPKs by E2 and different 
phytoestrogens
The most frequently reported and clearly defined pathway
for the rapid action of estrogens is the ERK pathway
[10,27-29]. Cholesterol did not induce a significant ERK
activation across this time course at a 10-7 M concentra-
tion (Figure 4A); TPA caused the expected robust ERK acti-
vation at early (5-10 min) and late (30 min) time points
(Figure 4B). E2 at a concentration of 10-9 M caused a rapid
activation of ERK (significant at 2.5 min). Then the
response decreased, followed by an additional activation
at 15 and again at 60 min (Figure 4C), similar to the oscil-
Proliferative effects of E2 in combination with different concentrations of phytoestrogens Figure 3
Proliferative effects of E2 in combination with different concentrations of phytoestrogens. GH3/B6/F10 cells were 
treated with different concentrations of phytoestrogens in the presence of either 10-9 M or 10-12 M E2. The cell numbers were 
measured after 3 days of treatment. (A) coumesterol (B) daidzein (C) genistein (D) trans-resveratrol. The solid horizontal line 
spans the reported concentrations of each estrogen in human serum or urine. * = p < 0.05 compared to 10-9 M E2. # = p < 0.05 
compared to 10-12 M E2.
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The time course of estrogenic phospho-activation of ERK Figure 4
The time course of estrogenic phospho-activation of ERK. Time-dependent activation of ERK measured by a quantita-
tive plate immunoassay in cells treated with (A) 10-7 M cholesterol (negative control), (B) 20 nM TPA (positive control), (C) 10-
9 M E2, (D) 10-8 M coumesterol, (E) 10-7 M daidzein, (F) 10-7 M genistein, (G) 10-7 M trans-resveratrol. * = p < 0.05 compared to 
vehicle only treated cells.
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lating activation that we observed previously [10,26,30].
Coumesterol at a concentration of 10-8 M caused a more
sustained activation of ERK, maintaining significance at
10 to 30 min (Figure 4D), also similar to previous obser-
vations [26]. Daidzein at a 10-7 M concentration increased
pERK at 5-10 min (Figure 4E), and genistein at this con-
centration at 10-15 min (Figure 4F). Trans-resveratrol at a
10-7 M concentration caused a significant increase of pERK
at 30 min only (Figure 4G).
Phosphorylation of other MAPKs
Other MAPKs such as JNK and p38 can also regulate cell
proliferation, though their exact roles are debated as to
whether they are proliferative or apoptotic [31]. We meas-
ured time-dependent phosphorylation of JNKs and p38s
in cells treated with E2 or phytoestrogens. Between 10 and
30 min, all estrogens increased levels of phosphorylated
JNK significantly (Figure 5) with slightly different peak
times. As for p38, only 10-9 M E2 increased phosphoryla-
tion of p38 at 15 and 60 min significantly; none of the
phytoestrogens changed phosphorylated p38 levels signif-
icantly (Figure 6). TPA activated both JNKs and p38s as
expected.
Signaling pathways involved in the proliferative effects of 
E2 and different phytoestrogens
To investigate whether ER α/β were involved in the prolif-
erative effects of phytoestrogens, we co-treated the cells
for 3 days with 1 nM ICI 182,780 (which depletes cellular
ER levels, [32]) and each estrogen separately: 10-9 M E2,
10-8 M coumesterol, and 10-7 M daidzein, genistein, and
trans-resveratrol. ICI 182,780 successfully blocked the
proliferative effects of all phytoestrogens (Figure 7A)
except  trans-resveratrol which showed no proliferative
effects. ERK antagonist (PD 98059, 10 μM), p38 antago-
nist (SB203580, 1 μM), and JNK antagonist (SP 600125,
5 μM) all attenuated the proliferative effect of all phytoes-
trogens examined (Figure 7B-D). The PKC antagonist (GF
109203X, 10 μM) did not change the proliferative effects
of any of these phytoestrogens (Figure 7E) suggesting that
these effects are selective for MAPK signaling pathways.
Caspase activity evoked by E2 and different 
phytoestrogens
Cell numbers can also be increased by other mechanisms
such as inhibition of apoptosis. Therefore, we measured
the activities of both caspase-8 (of the extrinsic pathway)
and caspase-9 (of the intrinsic pathway) in the cells
treated with E2 or different phytoestrogens. After 24 hours
of treatment, both the vehicle- and trans-resveratrol-
treated cells increased caspase-8 activity. For E2-, coumes-
terol-, daidzein-, and genistein-treated cells, the caspase-8
activity remained unchanged (Figure 8A). Caspase-9 activ-
ity showed no significant changes with any treatment (Fig-
ure 8B). Inhibition of caspase-8 activity with specific
antagonist, Ac-IETD-CHO in control cells confirmed the
involvement of caspase-8 (Figure 8C).
Activation of downstream targets of MAPKs by different 
phytoestrogens
Although the precise downstream events initiated by
MAPKs which result in cell proliferation are not clearly
understood, MAPKs are often shown to be part of the
pathway leading to that function. We measured the phos-
phorylation levels of two well-known downstream targets
for MAPKs: Elk-1 (Figure 9) and ATF-2 (Figure 10) result-
ing from treatment with E2 and different phytoestrogens.
We observed time-dependent changes in Elk phosphor-
ylation for most of these compounds at 15 min; daidzein
was slower (30 min) and coumesterol failed to activate
the transcription factor at all. Cells treated with 10-9 M E2
showed a sustained elevated level of Elk-1 phosphoryla-
tion up to 60 minutes, as did the positive control activator
TPA. Treatment with E2, TPA, and all phytoestrogens
caused elevations of phosphorylated ATF-2 at 10 minutes
followed by a rapid decline in all cases (Figure 10).
Discussion
Cell proliferation is a complex process under tight regula-
tion. Increasing cell number can be achieved by either
speeding up progress through the cell cycle or by decreas-
ing the amount or rate of cell death (frequently via the
process of apoptosis for known hormonal effects). We
demonstrated the proliferative effects of E2, and three of
four different phytoestrogens (coumesterol, daidzein,
genistein, but not trans-resveratrol) in a pituitary cell line
which expresses high levels of membrane ERα, an experi-
mental system well-suited to reveal the rapid actions of
estrogens and compounds which mimic them, as we have
done previously for other classes of estrogens [8,33-36].
Overall, our studies demonstrated that phytoestrogens
can elicit nongenomic responses (rapid ERK, JNK, tran-
scription factor and caspase activations) at concentrations
expected to be achieved by dietary intake. The low concen-
trations at which these activations occur suggest that these
nongenomic responses are relevant to common human
exposures.
In our mERα-enriched pituitary tumor cell line, cou-
mestrol, daidzein, and genistein increased cell prolifera-
tion with a lower potency than E2, but at concentrations
spanning known serum or urine levels in humans [12-
14,29]. However, trans-resveratrol did not change cell pro-
liferation at any concentration tested, so it is unlikely to
contribute to tumor cell growth at any exposure level,
while the other phytoestrogens might do this, if present
by themselves. However, lone exposure to phytoestrogens
is unlikely because physiological estrogens are usually
present across different life stages and for different sexes,
spanning ~pM to nM concentrations [37]). Interestingly,BMC Cancer 2009, 9:334 http://www.biomedcentral.com/1471-2407/9/334
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The time course of estrogenic phospho-activation of JNK Figure 5
The time course of estrogenic phospho-activation of JNK. Time-dependent activation of JNK measured by a quantita-
tive plate assay in cells treated with (A) 10-7 M cholesterol (negative control), (B) 20 nM TPA (positive control), (C) 10-9 M E2, 
(D) 10-8 M coumesterol, (E) 10-7 M daidzein, (F) 10-7 M genistein, (G) 10-7 M trans-resveratrol. * = p < 0.05 compared to vehicle 
only treated cells.
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The time course of estrogenic phospho-activation of p38 Figure 6
The time course of estrogenic phospho-activation of p38. Time-dependent activation of p38 measured by a quantita-
tive plate assay in cells treated with (A) 10-7 M cholesterol (negative control), (B) 20 nM TPA (positive control), (C) 10-9 M E2, 
(D) 10-8 M coumesterol, (E) 10-7 M daidzein, (F) 10-7 M genistein, (G) 10-7 M trans-resveratrol. * = p < 0.05 compared to vehicle 
only treated cells.
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The effects of different antagonists on the proliferative effect of phytoestrogens Figure 7
The effects of different antagonists on the proliferative effect of phytoestrogens. The proliferative effects of 10-9 M 
E2, 10-8 M coumesterol, 10-7 M daidzein, 10-7 M genistein and 10-7 M trans-resveratrol in the presence signaling molecule antag-
onists for: (A) ERα/β (ICI 182780, 1 nM) (B) ERKs (PD 98059, 10 μM) (C) p38 (SB203580, 1 μM) (D) JNK (SP 600125, 5 μM) 
(E) PKC (GF 109203×, 10 μM, negative control). * = p < 0.05 compared to control cells treated with vehicle only. # = p < 0.05 
compared to cells treated with antagonists only.
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The caspase activities of cells treated with phytoestrogens Figure 8
The caspase activities of cells treated with phytoestrogens. Caspase 8 and caspase 9 activities were measured in 
treated cells at the times indicated. Treatments were: vehicle control (Con), 10-7 M trans-resveratrol (Res), 10-7 M genistein 
(Gen), 10-7 M Daidzein (Dai), 10-8 M coumesterol (Cou), or 10-9 M E2. We measured (A) caspase 8 or (B) caspase 9 (n = 8). * = 
p < 0.05 compared to control. # = p < 0.05 compared between 2 and 24 hr. (C) To demonstrate the specificity of these 
actions by phytoestrogens on caspase 8, caspase 8 activity was attenuated by 5 μM caspase 8 inhibitor Ac-IETD-CHO 
(Con+Inh) measured at 24 hours, (n = 16). * = p < 0.05 compared to control. The caspase activity is expressed as change in flu-
orescence intensity (excitation wavelength of 400 nm and an emission wavelength of 505 nm) during an hr for 2500 cells.
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The time course of estrogenic phospho-activation of pElk-1 Figure 9
The time course of estrogenic phospho-activation of pElk-1. Time-dependent activation of Elk-1 by phosphorylation 
was measured by a quantitative plate immunoassay for phospho-Elk-1 (pELK-1) in cells treated with (A) 10-7 M cholesterol 
(negative control), (B) 20 nM TPA (positive control), (C) 10-9 M E2, (D) 10-8 M coumesterol, (E) 10-7 M daidzein, (F) 10-7 M gen-
istein, (G) 10-7 M trans-resveratrol. * = p < 0.05 compared to vehicle only treated cells.
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The time course of estrogenic phospho-activation of pATF-2 Figure 10
The time course of estrogenic phospho-activation of pATF-2. Time-dependent activation of ATF2 by phosphorylation 
was measured by a quantitative plate immunoassay for phospho-ATF-2 (pATF-2) in cells treated with (A) 10-7 M cholesterol 
(negative control), (B) 20 nM TPA (positive control), (C) 10-9 M E2, (D) 10-8 M coumesterol, (E) 10-7 M daidzein, (F) 10-7 M gen-
istein, (G) 10-7 M trans-resveratrol. * = p < 0.05 compared to vehicle only treated cells.
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10-7 M genistein treatment over 6-9 days was more robust
in maintaining cell proliferation than a physiological con-
centration of E2. The response differences between closely
related genistein and daidzein may be due to genistein's
higher bioavailbility [12]. Specific blockage by the ERα/β
antagonist ICI 182780 suggests that the proliferative
effects of E2, coumesterol, daidzein, and genistein involve
these ERs, most likely ERα for this cell line [8,38-40] since
they are enriched for mERα and under our conditions do
not appear to express ERβ.
We investigated co-treatments with E2 because these die-
tary estrogens have been suggested as foils for E2-mediated
cell growth. Whether E2 was delivered at low or high phys-
iological levels, all 4 tested phytoestrogens attenuated the
proliferative effects of E2, including low doses of trans-res-
veratrol (≥ 10-12 M) which did not cause proliferation by
itself. The increased effectiveness at the lower phytoestro-
gen doses is reminiscent of the non-monotonic dose-
responses that we have seen previously for nongenomic
responses to a variety of estrogens [35,36]. Several possi-
ble mechanisms could be involved including competition
for available ERs by the less potent phytoligands, differing
changes in the ERs' affinity or activation [41], or activa-
tions of multiple but different signaling pathways which
have different functional effects [13]. Whatever the mech-
anism, these data suggest that phytoestrogens at dietary
levels may be able to combat the proliferative effects of
the most prominent endogenous estrogen, E2, over a wide
range of physiological concentrations.
One of the best-characterized rapid actions of estrogens is
the phosphorylation of ERKs. The ERK pathway plays
important roles in cellular processes like proliferation, dif-
ferentiation, and survival. The oscillating and sustained
stimulation patterns we showed for E2 and coumestrol,
respectively, were similar to those previously observed by
us and others [26,42]. Daidzein and genistein caused
phosphorylation of ERK with similar early (5-10 min)
peaks, while trans-resveratrol caused increased pERKs sig-
nificantly only at a delayed (30 min) time point. These
data suggest that phytoestrogens can cause differential
(extent and pattern of oscillation) ERK activations, inter-
woven with probable deactivations by phosphatases [43].
The lack of early phase ERK activation by trans-resveratrol
may be related to its lack of proliferative effects. This is in
contrast to other reports that the later or sustained ERK
peak is more important for correlations to cell prolifera-
tion [44].
All tested phytoestrogens elicited JNK activation, with
only minor differences in timing, suggesting that the acti-
vation of this kinase was not responsible for differences in
controlling cell numbers between these compounds.
Phosphorylation of p38 could only be detected in E2-
treated cells, so its actions also do not correlate with the
proliferative abilities of these compounds. However, all
three MAPKs that we studied are apparently involved in
the signaling pathways important for GH3/B6/F10 cell pro-
liferation, as inhibitors selective for each of these kinases
attenuated cell proliferation, even in the vehicle control
group (suggesting that other baseline or hormone-irrele-
vant growth controls involve these enzymes). For exam-
ple, p38 has been related to bromocriptine-induced
apoptosis in rat pituitary GH3 cells [45]. Since all MAPKs
are involved, it is possible that they are differentially
involved, based on the timing of the oscillating phases of
kinase activation, to regulate cell proliferation [46]. How-
ever, all phytoestrogens inhibited proliferation when in
combination with E2. Perhaps this is related to the ability
of all of them to induce JNK phosphorylation with a sim-
ilar time course pattern. In addition, these phytoestrogens
could compete with E2 for binding to ERs and their roles
in the same proliferation pathways.
The significant changes we see in MAPK activities are
small, but many biological responses are probably modi-
fied in such small but significant increments, and they are
probably no less important than big changes for dialing
up and down functions. Our techniques for measuring
these responses have now improved (quantitative plate
immunoassays as opposed to Westerns), so that we can
finally measure the significance of these small changes
[10]. MAPKs receive lots of different signal inputs from
multiple pathways in cells, and adjust to each with a new
level of activity. Multiple small changes can add up to
large ones, with MAPKs essentially acting as a summation
device or a "rheostat". Activation of these kinases can
cause either immediate functional responses, and/or give
rise to eventual transcription of genes via phosphoryla-
tion of transcription factors, so some of these effects could
be downstream genomic actions.
Phytoestrogen-induced MAPK activations could lead to
downstream transcriptional events which might also
influence proliferative responses, such as we observed for
the phosphorylation of two known targets for MAPKs:
Elk-1 and ATF-2 [22,23]. Our data showed that two types
of time-dependent MAPK activations can be correlated
with Elk-1 and ATF-2 phosphorylations. ERK activation
just preceded or was coincident with the activations of
Elk-1, as would be expected if the activated kinase then
affects Elk-1 downstream. JNK activation was coincident
with the beginning of Elk-1 phosphorylation and could
participate in the subsequent (>15 min) Elk-1 phosphor-
ylations. ATF-2 phosphorylation being very fast and brief
in all cases is likely only affected by estrogen-induced ERK
activity. However, the high levels of phosphorylated ATF-
2 may suggest that other estrogen-induced mechanisms
also contribute, such as the rise in calcium levels, also
known to affect ATF-2 activation [47,48].BMC Cancer 2009, 9:334 http://www.biomedcentral.com/1471-2407/9/334
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Trans-resveratrol, a phytoestrogen which did not cause cell
proliferation on its own, increased phosphorylation of
ERKs with a delayed response, while its JNK, p38, Elk-1,
and ATF-2 responses did not differentiate it from the other
estrogens. This suggests that ERK activation parameters
were the most crucial for resveratrol's unique antiprolifer-
ative and perhaps pro-apoptotic (see below) actions. It
will be interesting in the future to discover which other
functional responses these activations may influence.
We further investigated the specific apoptotic pathways
involved in regulating cell number by separately assessing
the abilities of phytoestrogens to activate caspase-8 and
caspase-9, pivotal enzymes in the intrinsic and extrinsic
apoptosis pathways, respectively. Many types of cell treat-
ments can induce apoptosis, including removal of sera
from culture media, which can activate caspase-8, but
does not involve caspase-9 [49]. Estradiol and phytoestro-
gens (except trans-resveratrol) suppressed the activation of
caspase-8. The ability of resveratrol to inhibit the increase
in cell numbers caused by E2, though it could not itself
induce cell proliferation, could be due to its ability to
allow this apoptotic pathway to remain activated. It is
interesting that it is the extrinsic pathway which tradition-
ally involves receptors for extracellular ligands presented
at the cell membrane that is shown to be involved by our
studies. In combination with the rapid activation of
enzymes of the apoptotic pathway, this suggests a role for
a membrane form of steroid receptor, as our previous
studies have shown to be true for estrogenic responses in
this cell line [50-53] and for glucocorticoid-induced apop-
tosis in lymphoid cell lines [54].
Conclusion
Diet and nutrition are known to contribute to different
rates of cancer progression [1,55]. Our study has provided
evidence that different phytoestrogens can induce unique
cell number regulation effects whose contributing signal-
ing mechanisms can be multiple and complex. These dif-
ferent outcomes are probably cell type- and condition-
dependent, so our data will add to the body of knowledge
that must be accumulated in order to map out those dif-
ferences. However, it is clear that some of these mecha-
nisms are rapid and are likely to be mediated by
membrane receptors for estrogens, which in the case of
our model system is likely to be mERα. It is possible that
phytoestrogens, with their similar yet unique signaling
properties might be utilized as anti-tumor treatments, as
we and others have shown that they can oppose both
mechanisms and outcomes elicited by physiological
estrogens. At the same time women may benefit from
some of the other positive estrogenic signaling outcomes
if phytoestrogens are used as postmenopausal replace-
ment estrogens. Trans-resveratrol seems to be particularly
promising in this regard based on our studies. Investiga-
tors are now beginning to decipher the component signal-
ing pathways involved, so that we may eventually make
these therapeutic choices based on scientific evidence.
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